Português

Inglês

Home | Site Map | Add to Favorites Link | Send page to a Friend | Contact us

Revistas e artigos

Brazilian drug improves the immunity of dogs with leishmaniasis

A study published recently in the journal Acta Tropica has shown that P-MAPA, a drug developed in Brazil has shown effectiveness in improving the clinical state and immunity of dogs with symptoms of leishmaniasis

Brazilian drug shows potential against tuberculosis and cancer- August 2012

In an article recently published in Infectious Agents and Cancer, Brazilian and North American researchers showed that a drug developed in Brazil, called P-MAPA, is able to activate certain immune system receptors and helps fight tuberculosis and bladder cancer.

Nature Medicine- October 2011

Biomedicine in Brazil : Laws hinder drug development inspired by Amazonian biodiversity

THE LANCET - September 2010

A versatile new drug candidate called P-Mapa along with a new proposal to fight infectious diseases have emerged in Brazil. They are the result of collaboration among non-academic and academic groups in Brazil, Chile and the US led by the non-profit research network Farmabrasilis

E-DRUG - September 2010

News from Brazil: a new drug candidate and a new approach to fighting infectious diseases

SCIENCE IN AFRICA : November 2010

Brazilian and American scientists have demonstrated that a compound known as P-Mapa is active against Mycobacterium tuberculosis in vivo.

TropIKA : News from Farmabrasilis - April 2010

Tests carried out by Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) under contract signed by Farmabrasilis and US NIAID has shown that P-MAPA is active against M. tuberculosis in vivo.

TropiKA: Brazil-based network proposes new therapeutic approach for TB and other infectious diseases - April 2009

TropIKA: Farmabrasilis is a non-governmental, non-profit research network bringing together Brazilian, Chilean, American and European scientists and others whose concern is: “The research and development of new medicines and technologies for the benefit of economically disadvantaged populations and individuals affected by neglected diseases”.

P-MAPA against visceral leishmaniaisis

Lethal infection caused by a single cell parasite, visceral leishmaniasis spreads throughout Brazilian cities.Among the compounds currently being tested against leishmaniasis, at least one was entirely developed in Brazil by the research network Farmabrasilis. The compound is P-MAPA, an acronym for protein magnesium ammonium phospholinoleate anhydride polymer. In tests conducted in Brazil and in the United States, it has proven to be effective against Listeria monocytoges bacteria, whose survival mechanism in the organism is similar to that of the protozoa of the Leishmania genera.

Lógica Digital

Privacy Policy | Legal | copyright@2.006-farmabrasilis- all rights reserved